You cannot register for this webinar

Dr. Nils Wellhausen of the University of Pennsylvania will share groundbreaking insights into the potential of epitope editing to revolutionize immunotherapies for blood cancers and HIV reservoir elimination. Over the past two decades, antigen-directed immunotherapies like CAR-T cells, monoclonal antibodies (mAbs), and bispecific T cell engagers (BTEs) have transformed oncology. However, their effectiveness has been limited by challenges in identifying antigens that are uniquely expressed on cancer cells, leading to off-tumor toxicity and fragmented therapeutic approaches. Dr. Wellhausen presents an innovative solution: a CD45-focused immunotherapy platform that leverages targeted CRISPR base editing to enable safe and effective treatment of hematologic malignancies and HIV reservoirs. In this upcoming live webinar, Dr. Wellhausen will cover: - Epitope Editing for Targeted Therapy: Dr. Wellhausen and team developed an epitope-edited hematopoietic stem cell and CAR-T cell pair enabling CD45-directed immunotherapies with reduced off-tumor toxicity while preserving CD45 function. - Effective Against Blood Cancers: Epitope-edited CD45 CAR-T cells showed efficacy in targeting diverse blood cancers while maintaining healthy hematopoiesis through regeneration by edited hematopoietic stem cells. - Versatility: The CD45 platform demonstrated compatibility with multiple therapeutic modalities, including bispecific T-cell engagers (BTEs), broadening its applications across hematopoietic diseases, including HIV. - HIV Reservoir Eradication: Multiplex base editing of CD45 and CCR5 generated HIV-resistant CART45 cells that successfully depleted HIV-infected CD4+ T cells in mouse models. - Advanced Editing Analysis: The Tapestri Genome Editing Solution characterized editing outcomes, revealing high co-occurrence of precise edits with minimal off-target effects, ensuring the reliability of the editing approach.